{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"389","upperLimit":"18,667","value":"5700"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6","upperLimit":"9,718","value":"668"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Prior to Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"Limit to 41 evaluable patients who received dose 1.8 mg/kg","dispersionType":"Full Range","groups":[{"description":"Evaluable patients who received dose 1.8mg/kg.","id":"OG000","title":"Dose 1.8mg/kg"}],"paramType":"MEDIAN","populationDescription":"4 eligible patients did not consent for genetic studies. 3 of the 41 did not have baseline TARC and 6 did not have TARC prior to cycle 2.","reportingStatus":"POSTED","timeFrame":"From baseline to time prior to cycle 2","title":"Plasma Level of Thymus and Activation-Regulated Chemokine (TARC)","type":"SECONDARY","unitOfMeasure":"pg/ml"}